MA31146B1 - Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation - Google Patents
Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisationInfo
- Publication number
- MA31146B1 MA31146B1 MA32069A MA32069A MA31146B1 MA 31146 B1 MA31146 B1 MA 31146B1 MA 32069 A MA32069 A MA 32069A MA 32069 A MA32069 A MA 32069A MA 31146 B1 MA31146 B1 MA 31146B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulas
- compounds
- methods
- phosphoinositide
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
L'invention concerne des composés représentés par les formules Ia-d, dans lesquelles X représente S ou O, mor représente un groupe morpholine et R3 représente un groupe hétéroaryle monocyclique, y compris les stéréo-isomères, les isomères géométriques, les tautomères, les solvates, les métabolites et les sels pharmaceutiquement acceptables de ces composés, ces composés étant utiles pour moduler l'activité de kinases lipidiques comprenant PI3K, et dans le traitement de troubles tels que le cancer induits par des kinases lipidiques. L'invention concerne des procédés d'utilisation des composés représentés par les formules Ia-d pour le diagnostic in vitro, in situ et in vivo, le traitement prophylactique ou thérapeutique de tels troubles ou d'états pathologiques associés dans des cellules de mammifère. [Insérer formules Ic et Id]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87344806P | 2006-12-07 | 2006-12-07 | |
US97725707P | 2007-10-03 | 2007-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31146B1 true MA31146B1 (fr) | 2010-02-01 |
Family
ID=39188533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32069A MA31146B1 (fr) | 2006-12-07 | 2009-07-02 | Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation |
Country Status (22)
Country | Link |
---|---|
US (3) | US7888352B2 (fr) |
EP (2) | EP2114949A1 (fr) |
JP (1) | JP5284977B2 (fr) |
KR (1) | KR101460816B1 (fr) |
AR (1) | AR064155A1 (fr) |
AU (1) | AU2007329352B2 (fr) |
BR (1) | BRPI0717923A2 (fr) |
CA (1) | CA2671782C (fr) |
CL (1) | CL2007003520A1 (fr) |
CO (1) | CO6190615A2 (fr) |
CR (1) | CR10915A (fr) |
EC (1) | ECSP099496A (fr) |
ES (1) | ES2544082T3 (fr) |
MA (1) | MA31146B1 (fr) |
MX (1) | MX2009005950A (fr) |
MY (1) | MY180595A (fr) |
NO (1) | NO20092566L (fr) |
NZ (1) | NZ578162A (fr) |
PE (1) | PE20081679A1 (fr) |
RU (1) | RU2468027C2 (fr) |
TW (1) | TWI499420B (fr) |
WO (1) | WO2008070740A1 (fr) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1953417B (zh) * | 1996-09-04 | 2010-12-29 | 英特托拉斯技术公司 | 一种从用户站点向外部站点发布使用数据的方法 |
EP2041139B1 (fr) * | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Composés pharmaceutiques |
JP5284977B2 (ja) * | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
RU2470936C2 (ru) | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
EP2158207B1 (fr) * | 2007-06-12 | 2011-05-25 | F. Hoffmann-La Roche AG | Thiazolopyrimidines et leur utilisation comme inhibiteurs de la phosphatidylinositol-3 kinase (pi3k) |
RU2523890C2 (ru) * | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
CA2704711C (fr) | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Composes inhibiteurs de la pi3k a base de thiazolopyrimidine |
EP2214675B1 (fr) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Procédé de préparation de composés de thiénopyrimidine |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
PE20091158A1 (es) | 2007-12-19 | 2009-08-28 | Genentech Inc | 5-anilinoimidazopiridinas y metodos de uso |
CA2710194C (fr) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibiteurs de la p13 kinase |
KR20100099185A (ko) | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | 아자인돌리진 및 이용 방법 |
TWI675668B (zh) | 2008-03-18 | 2019-11-01 | 美商建南德克公司 | 抗her2抗體-藥物結合物及化療劑之組合及使用方法 |
RU2473549C2 (ru) * | 2008-07-31 | 2013-01-27 | Дженентек, Инк. | Пиримидиновые соединения, композиции и способы применения |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
WO2010042998A1 (fr) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | Modulateurs des récepteurs s1p |
CA2740484C (fr) * | 2008-10-17 | 2021-09-21 | Akaal Pharma Pty Ltd | Modulateurs des recepteurs s1p et leur utilisation |
KR101430424B1 (ko) | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
AU2010224125B2 (en) * | 2009-03-12 | 2015-05-14 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
CN102361878A (zh) | 2009-03-24 | 2012-02-22 | 住友化学株式会社 | 用于制备硼酸酯化合物的方法 |
JP5781066B2 (ja) | 2009-05-27 | 2015-09-16 | ジェネンテック, インコーポレイテッド | p110δに対して選択的な二環式ピリミジンPI3K阻害剤化合物及び使用方法 |
WO2010136491A1 (fr) * | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Composés bicycliques indole-pyrimidine inhibiteurs de pi3k sélectifs pour p110 delta et leurs procédés d'utilisation |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
CN102625807B (zh) | 2009-09-08 | 2016-03-09 | 霍夫曼-拉罗奇有限公司 | 4-取代的吡啶-3-基-甲酰胺化合物和使用方法 |
KR101449217B1 (ko) | 2009-09-28 | 2014-10-08 | 에프. 호프만-라 로슈 아게 | 벤즈옥세핀 pi3k 억제제 화합물 및 사용 방법 |
CA2776944A1 (fr) * | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek |
WO2011049625A1 (fr) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Procédé de criblage d'aflatoxine dans des produits |
CN105801550B (zh) | 2009-11-05 | 2019-06-14 | 理森制药股份公司 | 新型苯并吡喃激酶调节剂 |
BR112012011147A2 (pt) * | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
KR101469334B1 (ko) * | 2009-11-12 | 2014-12-04 | 에프. 호프만-라 로슈 아게 | N-9-치환된 퓨린 화합물, 조성물 및 사용 방법 |
BR112012019635A2 (pt) | 2010-02-22 | 2016-05-03 | Hoffmann La Roche | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso |
EP2552428A1 (fr) | 2010-03-30 | 2013-02-06 | Novartis AG | Inhibiteurs de la protéine kinase c (pkc) pour le traitement d'un lymphome b à signalisation active chronique des récepteurs des cellules b active chronique |
KR101531117B1 (ko) | 2010-07-14 | 2015-06-23 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대해 선택적인 퓨린 화합물, 및 사용 방법 |
ES2530545T3 (es) | 2010-12-16 | 2015-03-03 | Hoffmann La Roche | Compuestos tricíclicos inhibidores de la PI3K y métodos de uso |
RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
RU2013143747A (ru) | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
RS54903B1 (sr) | 2011-04-01 | 2016-10-31 | Curis Inc | Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink |
EA024842B9 (ru) | 2011-05-04 | 2017-08-31 | Ризен Фармасьютикалз Са | Соединения в качестве модуляторов протеинкиназы pi3k |
EP2524918A1 (fr) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines en tant qu'inhibiteurs de kinase |
RU2013154355A (ru) * | 2011-06-03 | 2015-07-20 | Ф. Хоффманн-Ля Рош Аг | Способ лечения мезотелиомы ингибитором рi3к |
ES2592219T3 (es) * | 2011-10-07 | 2016-11-28 | Cellzome Limited | Derivados de {(4-(4-morfolino-dihidrotieno[3,4-d]pirimidin-2-il)aril}urea o carbamato como inhibidores de mTOR |
CN105062961A (zh) | 2012-05-23 | 2015-11-18 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
AU2013273489B9 (en) | 2012-06-08 | 2018-08-23 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
MX357043B (es) | 2012-07-04 | 2018-06-25 | Rhizen Pharmaceuticals Sa | Inhibidores selectivos de pi3k delta. |
WO2014022728A1 (fr) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Dérivés 5-(quinazolin-2-yl)pyrimidin-2-amines substitués utiles comme inhibiteurs de pi3k/mtor pour le traitement du cancer |
CA2879597C (fr) | 2012-08-21 | 2021-01-12 | Opko Pharmaceuticals, Llc | Formulation ophtalmique de liposomes pour traitement des maladies du segment posterieur |
WO2014033196A1 (fr) * | 2012-08-30 | 2014-03-06 | F. Hoffmann-La Roche Ag | Composés dioxino- et oxazine-[2,3-d]pyrimidine, inhibiteurs de pi3k, et leurs procédés d'utilisation |
JP6123097B2 (ja) * | 2012-10-10 | 2017-05-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | チエノピリミジン化合物を製造するための方法 |
WO2014068070A1 (fr) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prévenir le syndrome des antiphospholipides (sapl) |
WO2014180752A1 (fr) | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Procédé pour préparer des produits intermédiaires d'acide boronique |
WO2014203129A1 (fr) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinaisons de composés benzopyrane, leurs compositions et utilisations |
CN105985354B (zh) * | 2015-02-09 | 2020-10-02 | 南京盖特医药技术有限公司 | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
CA2981159A1 (fr) | 2015-06-29 | 2017-01-05 | F. Hoffmann-La Roche Ag | Methodes de traitement avec du taselisib |
AR105238A1 (es) | 2015-07-02 | 2017-09-20 | Hoffmann La Roche | Compuestos de benzoxacepina oxazolidinona y métodos de uso |
CN107995911B (zh) * | 2015-07-02 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
WO2017013270A1 (fr) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Utilisation d'un inhibiteur de la signalisation de la leptine pour la protection des reins de patients atteints de ciliopathie |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
MX2019004842A (es) * | 2016-11-02 | 2019-06-20 | Curis Inc | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. |
CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US11459306B2 (en) | 2017-07-31 | 2022-10-04 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia |
AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
US11613549B2 (en) | 2018-01-23 | 2023-03-28 | Basf Se | Bromination of pyridine derivatives |
WO2019157516A1 (fr) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Polythérapies |
WO2019199874A1 (fr) * | 2018-04-10 | 2019-10-17 | Neuropore Therapies, Inc. | Dérivés de morpholine en tant qu'inhibiteurs de vps34 |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
CA3099118A1 (fr) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
CA3099045A1 (fr) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
CA3098885A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
EP4268898A3 (fr) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
CN112423843B (zh) | 2018-06-15 | 2023-11-28 | 詹森药业有限公司 | 雷帕霉素类似物和其用途 |
EP3849554A4 (fr) | 2018-09-11 | 2022-06-01 | Curis, Inc. | Polythérapie avec un inhibiteur de phosphoinositide 3-kinase ayant une fraction de liaison au zinc |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020103897A1 (fr) * | 2018-11-22 | 2020-05-28 | 上海迪诺医药科技有限公司 | Dérivé de pyrimidine condensée hétérocyclique, composition pharmaceutique associée et application associée |
WO2020132651A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Inhibiteurs de kif18a |
JP2022513971A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
WO2020132648A1 (fr) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Inhibiteurs de kif18a |
MX2021007158A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
EP3903828A4 (fr) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase |
US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
WO2020180768A1 (fr) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Composés hétéroaryle bicycliques et leurs utilisations |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
CA3147451A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
JP2022542319A (ja) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
WO2021076655A1 (fr) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Multithérapie d'inhibiteur de kras et d'inhibiteur de shp2 pour le traitement de cancers |
CA3155857A1 (fr) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Derives de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
WO2021091956A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
JP2022553857A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
EP4054719A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
EP4055017A1 (fr) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Composés hétéroaryles bicycliques et leurs utilisations |
AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
CA3158188A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthese amelioree de compose inhibiteur de kras g12c |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
CA3163680A1 (fr) | 2019-12-05 | 2021-06-10 | David John O'neill | Analogues de la rapamycine et leurs utilisations |
WO2021126816A1 (fr) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Schéma posologique d'un inhibiteur du kras g12c |
CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
WO2021257736A1 (fr) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Méthodes de retardement, de prévention et de traitement de la résistance acquise aux inhibiteurs de ras |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
CA3203111A1 (fr) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Inhibiteurs de sos1 et utilisations associees |
WO2022235870A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras pour le traitement du cancer |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2022235864A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
DE2050814A1 (de) | 1970-10-16 | 1972-04-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen |
DE1959403A1 (de) | 1969-11-26 | 1971-06-03 | Thomae Gmbh Dr K | Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
CH592668A5 (fr) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4196207A (en) * | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
WO1993013664A2 (fr) | 1992-01-11 | 1993-07-22 | Schering Agrochemicals Limited | Composes fongicides biheterocycliques |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びpi3キナーゼ阻害剤 |
JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3キナーゼ阻害剤とその製造法 |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
AUPO903897A0 (en) | 1997-09-08 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Organic boronic acid derivatives |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
KR100446363B1 (ko) | 1997-11-11 | 2004-09-01 | 화이자 프로덕츠 인코포레이티드 | 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체 |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
WO2002056912A2 (fr) | 2001-01-16 | 2002-07-25 | Glaxo Group Limited | Methode de traitement du cancer |
CA2454976C (fr) | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Agent therapeutique contre le glaucome contenant en tant qu'ingre dient actif un compose presentant un effet inhibiteur de la kinase pi3 |
US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
WO2003034997A2 (fr) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulateurs de la phosphoinositide 3-kinase |
EP1444010A2 (fr) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Derives de carboxamide heteroaromatique destines au traitement des inflammations |
EP1531813A1 (fr) | 2002-07-10 | 2005-05-25 | Applied Research Systems ARS Holding N.V. | Utilisation de composes pour accroitre la motilite des spermatozoides |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
JP4782564B2 (ja) | 2002-07-10 | 2011-09-28 | メルク セローノ ソシエテ アノニム | アゾリジノン−ビニル縮合−ベンゼン誘導体 |
WO2004017950A2 (fr) | 2002-08-22 | 2004-03-04 | Piramed Limited | Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux |
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
JP4862654B2 (ja) * | 2004-10-08 | 2012-01-25 | アステラス製薬株式会社 | 芳香環縮合ピリミジン誘導体 |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
EP2041139B1 (fr) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Composés pharmaceutiques |
AU2007242594A1 (en) | 2006-04-26 | 2007-11-01 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
UA95799C2 (en) * | 2006-04-26 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Pharmaceutical compounds |
CN101511840A (zh) * | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
JP5284977B2 (ja) | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
RU2470936C2 (ru) | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
-
2007
- 2007-12-05 JP JP2009540459A patent/JP5284977B2/ja active Active
- 2007-12-05 KR KR1020097014134A patent/KR101460816B1/ko active IP Right Grant
- 2007-12-05 US US11/951,203 patent/US7888352B2/en active Active
- 2007-12-05 BR BRPI0717923-5A2A patent/BRPI0717923A2/pt not_active Application Discontinuation
- 2007-12-05 CL CL200703520A patent/CL2007003520A1/es unknown
- 2007-12-05 PE PE2007001726A patent/PE20081679A1/es active IP Right Grant
- 2007-12-05 AU AU2007329352A patent/AU2007329352B2/en not_active Ceased
- 2007-12-05 MX MX2009005950A patent/MX2009005950A/es active IP Right Grant
- 2007-12-05 RU RU2009125897/04A patent/RU2468027C2/ru not_active IP Right Cessation
- 2007-12-05 NZ NZ578162A patent/NZ578162A/en not_active IP Right Cessation
- 2007-12-05 ES ES12177885.6T patent/ES2544082T3/es active Active
- 2007-12-05 AR ARP070105449A patent/AR064155A1/es unknown
- 2007-12-05 WO PCT/US2007/086543 patent/WO2008070740A1/fr active Application Filing
- 2007-12-05 MY MYPI20092322A patent/MY180595A/en unknown
- 2007-12-05 TW TW096146344A patent/TWI499420B/zh not_active IP Right Cessation
- 2007-12-05 EP EP07854962A patent/EP2114949A1/fr not_active Withdrawn
- 2007-12-05 EP EP12177885.6A patent/EP2518074B1/fr active Active
- 2007-12-05 CA CA2671782A patent/CA2671782C/fr not_active Expired - Fee Related
-
2009
- 2009-07-02 MA MA32069A patent/MA31146B1/fr unknown
- 2009-07-06 CR CR10915A patent/CR10915A/es unknown
- 2009-07-06 NO NO20092566A patent/NO20092566L/no not_active Application Discontinuation
- 2009-07-07 EC EC2009009496A patent/ECSP099496A/es unknown
- 2009-07-07 CO CO09070151A patent/CO6190615A2/es active IP Right Grant
-
2010
- 2010-12-23 US US12/978,106 patent/US8383620B2/en active Active
-
2013
- 2013-01-10 US US13/738,829 patent/US8993563B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31146B1 (fr) | Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation | |
MX2009005925A (es) | Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso. | |
MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
MA33614B1 (fr) | Composés de benzoxépine inhibiteurs de pi3k et leurs procédés d'utilisation | |
MA31339B1 (fr) | Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation | |
CN104136442B (zh) | 作为离子通道调节剂的吡喃‑螺环哌啶酰胺类 | |
RU2434865C2 (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов | |
TW200801012A (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
MA32271B1 (fr) | Composes inhibiteurs de kinases raf et procedes d'utilisation | |
TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
WO2008005956A3 (fr) | Inhibiteurs de pyrrolotriazine kinase | |
MA31178B1 (fr) | Dérivés de 3-amino-pyrrolo[3,4-c]pyrazole-5-(1h,4h, 6h) carbaldéhyde servant d'inhibiteurs de pkc | |
MA34234B1 (fr) | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation | |
MA30952B1 (fr) | Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt | |
GB0018528D0 (en) | Compounds | |
WO2009036082A3 (fr) | Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
TW200413331A (en) | Small molecule PI 3-kinase inhibitors and methods of their use | |
MA27883A1 (fr) | Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv | |
NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
NO20072409L (no) | Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser | |
NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer |